September 25, 2025Frontiers in OncologyOpen Access

Benefit-risk evaluation of Fuzheng Yiliu Decoction combined with chemotherapy for treating non-small cell lung cancer using multicriteria decision analysis

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Multi-criteria decision analysis shows benefit-risk advantages of Fuzheng Yiliu Decoction in NSCLC, indicating improved outcomes.

Combining fuzheng yiliu decoction with chemotherapy improved therapeutic efficacy in NSCLC patients, suggesting a viable treatment strategy.
The benefit-risk value for combination therapy was 68, significantly higher than 27 for chemotherapy alone, indicating a promising approach.
Meta-analysis identified 6 randomized controlled trials, providing robust evidence for the superiority of combination treatment over chemotherapy alone.
Monte Carlo simulations showed an 81.83% probability that the combination therapy’s benefit-risk value exceeds that of chemotherapy alone.

Ma et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

September 25, 2025Frontiers in OncologyOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Multi-criteria decision analysis shows benefit-risk advantages of Fuzheng Yiliu Decoction in NSCLC, indicating improved outcomes.

Combining fuzheng yiliu decoction with chemotherapy improved therapeutic efficacy in NSCLC patients, suggesting a viable treatment strategy.
The benefit-risk value for combination therapy was 68, significantly higher than 27 for chemotherapy alone, indicating a promising approach.
Meta-analysis identified 6 randomized controlled trials, providing robust evidence for the superiority of combination treatment over chemotherapy alone.
Monte Carlo simulations showed an 81.83% probability that the combination therapy’s benefit-risk value exceeds that of chemotherapy alone.

Ma et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark